On September 21, 2016 the stock rating was rated “Hold” according to a Johnson Rice report a cut from the previous “Buy” rating. On July 25 the stock rating was downgraded from “” to “Neutral” and a price target of $38.00 was set in a ...
Cannabis Science Inc (CBIS) investors sentiment NaN in Q4 2016 ... Finally, from a technical perspective, there's a strong possibility that the stock could enter into a new bull market after finding strong support between $34.26 and $34.43.
CBIS stock, or Cannabis Sciences Inc. (OTCMKTS: CBIS), is up another 13% today (Thursday) after it soared 30% Wednesday. Based in Colorado Springs, Colo., Cannabis Sciences develops a wide range of cannabinoid-based …
Over the past year, the CBIS stock has traded as high as approximately $0.14, and a low around $0.01, shares currently trade around $0.075. The company is working to discover and develop novel cannabinoid-based therapies to improve the …
One stock called Cannabis Science (CBIS) is a good example of what we mean. That’s the wrong question to ask. Because there are so many cannabis stock investing scams that the SEC had to issue a warning, the right question to …
So far, that hasn’t been a very good bet for investors. Shares of CBIS stock are off 34% for the year-to-date, and — again — like all medical marijuana stocks, they are volatile. Cannabis Science stock was actually up about 90% back in …
Cannabis Science Inc (OTCMKTS:CBIS) shares have been down over 15% in a one-month period and over 40% in a …
In the last trading session, the stock price of Cannabis Science Inc (OTCMKTS:CBIS) jumped more than 10% to close the week at $0.0663. The gains came at a share volume of 28.20 million compared to average share volume of 15.13 …
In this video, we look at the cannabis stock CBIS Cannabis Science INC. The OTC marijuana stocks like this one were quite bearish after the election on November 8 2016, but in the last couple weeks the volumes have picked up and a lot …
On July 25 the stock rating was downgraded from “” to “Neutral” with a current price target of $38.00 by analysts at Citigroup. On July 22 the company was downgraded to “Neutral” from “Outperform” by Baird. On May 16 the company …